21-24 November 2024

29TH Annual meeting & Education Day of the Society for Neuro-Oncology Houston, Texas

The Society for Neuro-Oncology is a multidisciplinary organization dedicated to promoting advances in neuro-oncology through research and education.

Novocure presentations schedule

Friday, November 22

06:45 - 06:55 (America/Denver)

Oral Presentation

Phase 1 trial of personalized neoantigen vaccines in combination with standard care to treat glioblastoma

Chair(s): S. Cheng, S.J. Chen, C.C. Bozkus, A. Rubinstyn, J. Kodysh, T. O’Donnell, M. Saxena, G. Akturk, M. Meseck, R. Yong, B. Losic, J. Mandeli, R.S. Kim, S. Gnjatic, N. Bhardwaj, A. Hormigo

Learn more

Saturday, November 23

10:50 - 10:55 (America/Denver)

Oral Presentation

Tumor Treating Fields (TTFields) therapy with chemoradiation, followed by maintenance TTFields therapy/temozolomide (TMZ), in newly diagnosed glioblastoma (ndGBM). Results of phase II clinical study. 

Chair(s): R. Grossmann

Sunday, November 24

07:30 - 09:00 (America/Denver)

Oral Presentation

Newly designed Tumor Treating Fields (TTFields) arrays for the mouse head demonstrate efficacy for treatment of glioblastoma

Chair(s): S. Zbidat, R. Blatt, M. Sellevoll, M. Gabay, I. Schlachet, S. Cahal, S. Davidi, I. Tzchori, A. Haber, M. Giladi, Y. Palti

Friday, November 22

06:30 - 08:30 (America/Denver)

Poster

Outcomes of patients with isocitrate dehydrogenase-mutant WHO Grade 4 astrocytoma treated with Tumor Treating Fields (TTFields) therapy: a real-world analysis

Chair(s): J.M. Connelly, N. Avgeropoulos, P. Conlon, G. Chavez, O. Farber

Friday, November 22

06:30 - 08:30 (America/Denver)

Poster

Long-term survival and patterns of progression in patients with newly diagnosed glioblastoma treated with or without Tumor Treating Fields (TTFields) in a real-world setting

Chair(s): Riegel D, Bureau B, Conlon P, Chavez G, Connelly J

Friday, November 22

06:30 - 08:30 (America/Denver)

Poster

Delivery of TTFields to the infratentorial brain using HFE arrays

Chair(s): D Bhavanasi, O. Ze’evi, A. Naveh, D. Manzur, N. Shapira

Friday, November 22

06:30 - 08:30 (America/Denver)

Poster

Feasibility evaluation of Tumor Treating Fields (TTFields) therapy for brainstem gliomas
 

Chair(s): W. Shi, B. Berger, N. Urman

Friday, November 22

06:30 - 08:30 (America/Denver)

Poster

Tumour Treating Fields (TTFields) and DNA damage response (DDR) inhibitors enhance glioma cell death through chemo-/radiosensitisation

Chair(s): C.G. Jones, A. Vanderlinden, K.N. Myers, C. McGarrity-Cottrell, O. Rominiyi, S. Collis

Friday, November 22

06:30 - 08:30 (America/Denver)

Poster

The impact of Tumor Treating Fields on cancer stem-like cells isolated from the subventricular zone of glioblastoma patients

Chair(s): Y. Licón Muñoz, R.B. Sidebottom, S. Varela

Friday, November 22

06:30 - 08:30 (America/Denver)

Poster

Transmembrane water efflux rate (kio) is an MRI-detectable biomarker to evaluate the efficiency of TTFields treatment on glioblastoma

Chair(s): Songtao Hu, Yinhang Jia, Qingping He, Jiaqi Chu, Yongjie W, Ruiliang Bai

Novocure Websites

This website is intended for people seeking information on Novocure’s worldwide business.



All rights reserved.

MyLink, MyNovocure, Novocure, and Optune Gio are trademarks of Novocure GmbH.

All other trademarks, registered or unregistered, are the property of their respective owners.

MED-GL-PAN-2400032